Metabolomic profiling reveals grade-specific niacinamide accumulation and its therapeutic potential via SIRT1-CD38-EMT axis modulation in cervical cancer progression
Despite new therapies for cervical cancer, innovative strategies are essential to overcome drug resistance and high toxicity. The present study focuses on the metabolic profiling of cervical carcinoma using a non-targeted metabolomics approach using liquid chromatography-mass spectrometry. Our study identified over 70 metabolites in cervical tissue samples (both cancerous and adjacent normal) using HILIC and reversed-phase chromatography in the positive and negative ionization modes. Major metabolic alterations included changes in nicotinamide metabolism, ammonia recycling, amino acid metabolism and nucleotide metabolism, in a grade-dependent manner. Compared to normal tissue, HPV-positive tumors showed elevated nicotinamide metabolism, and phosphatidylethanolamine biosynthesis, whereas HPV-negative tumors showed enriched purine and pyrimidine metabolism. We validated our findings by analyzing transcriptomics datasets from the Gene Expression Omnibus database to understand the expression patterns of the underlying genes involved in the dysregulated pathways. We observed that nicotinamide metabolism exhibits significant effects in lower-grade cervical cancers and specific HPV genotypes. We treated cervical cancer cell lines with niacinamide (NAM), an amide form of niacin, to evaluate its therapeutic efficacy. NAM treatment modulated NAD
Authors
Funding
Wellcome Trust FundingDBT-Wellcome Trust India Alliance Grant IA/E/17/1/503663Indian Council of Medical Research FundingDepartment of Biotechnology, Ministry of Science and Technology, India FundingDepartment of Science and Technology, Ministry of Science and Technology, India Grant SR/FST/LS-II/2017/115Department of Science and Technology, Government of Rajasthan FundingWellcome Trust DBT India Alliance Grant IA/E/17/1/503663Science and Engineering Research Board Grant CRG/2023/001776